Infantile Hemangioma: A Current Review

J Pediatr Hematol Oncol. 2022 Mar 1;44(2):31-39. doi: 10.1097/MPH.0000000000002384.


Infantile hemangiomas (IHs) are common vascular lesions which are benign but can cause significant functional and cosmetic morbidity. Since the fortuitous discovery of propranolol being effective to treat IH over a decade ago, the therapy and prognosis for children with IH have improved dramatically. Oral propranolol (as well as other oral beta-blockers and topical timolol) are safe and effective treatments, and have now supplanted other therapies. Making the correct diagnosis is crucial, because other vascular lesions can mimic IH. In addition, IH can be the first manifestation of an underlying syndrome. For IH requiring treatment, initiating treatment early is key to optimizing success. Therefore, early recognition and referral, if necessary, are important. Continued research on IH, both basic science and clinical, should result in continued advances.

Publication types

  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Child
  • Hemangioma* / diagnosis
  • Hemangioma* / drug therapy
  • Humans
  • Infant
  • Propranolol / therapeutic use
  • Skin Neoplasms* / diagnosis
  • Timolol / therapeutic use
  • Treatment Outcome


  • Adrenergic beta-Antagonists
  • Timolol
  • Propranolol